Home > Focus Areas > Obesity Connect > Post
  • Saved

6d
How do safety and tolerability influence obesity treatment decisions?

Obesity management has evolved with newer pharmacologic therapies demonstrating meaningful efficacy, yet safety and tolerability remain central to treatment selection. Adverse effects, patient preferences, and long-term adherence all influence whether a treatment is started, continued, or switched in routine practice.

Gastrointestinal adverse events are among the most commonly reported considerations with current pharmacologic therapies for obesity, including nausea, vomiting, and diarrhea. These effects are often mild to moderate and more frequent during dose escalation, but they can still affect treatment persistence. Safety profiles vary across therapeutic classes, and clinicians must also consider less common adverse events, such as gastrointestinal complications or gallbladder-related events, as well as class-specific considerations that may require monitoring.

Patient factors should guide therapy choice, including comorbidities, prior treatment experience, weight-loss goals, and the likelihood of sustained adherence. In practice, the most appropriate option is often the one that best balances efficacy with an acceptable safety profile for the individual patient.

How do you weigh efficacy versus tolerability when selecting pharmacologic therapies for obesity? What patient factors most influence your decision to initiate or switch treatment in obesity management?

Profile Image
  • 6d
    The factors the determine the initial choice is often the co-morbid factors and the total weight loss needed.
  • 6d
    Obviously it's degrees. For someone who has a lot of comorbids and severe obesity, then I will accept a lot more risk, then someone with BMI of 31 and no risk factors.
  • 1w
    Obesity is a chronic medical problem and we have to address underlying issues that lead to overeating are expensive and more and more side effects are surfacing-medications are a short term fix but patients have to make lifestyle changes
  • 1w
    Patients have different thresholds for ASE acceptance . It all depends on how much and how long they’re willing to cope with ASE’s in order to achieve their weight loss goal . Once they do , in most instances the ASE’s become part of every day life as long as the weight loss is maintained and the budget allows it.
  • 1w
    I explain the different options to the patient, explain risks/ benefits, the choice of medication depends a lot of insurance coverage, price of medication.
  • 1w
    I believe everyone is entitled to an opportunity to try weight loss medicine if they desire as long as there is no absolute contraindications like MEN, MTC, or prior hypersensitivity. Even low doses can provide benefit. The main inhibition at this point is out of pocket cost / insurance coverage
  • 1w
    For many patients, especially with newer incretin-based therapies like Semaglutide or Tirzepatide, the limiting factor isn’t efficacy,it’s GI tolerability. Nausea, early satiety, and occasional vomiting tend to cluster during dose escalation.
  • 2w
    The need, the desire and if it is an appropriate request. Efficacy can be seen just by how much weight is the person losing. Now tolerability can be tricky and for most education is key. Sometimes and antiemetic and increase in fluid intake is enough to combat most adverse affects. For more serious intolerances than switching or discontinuing medications may be necessary. Close monitoring especially after dose increases will help combat issues early
  • 2w
    I order what ever the insurance covers, then if side effects change the injectable. Oral versus injectable patient preference.
  • 3w
    I work with the patient's wushses but mostly use oral glp-1 and
    had no problems.
  • 3w
    efficacy with glp-1 class has never been an issue with injectables and orals but tolerability is always of concern. Usually oral GLP-1s are hard to tolerate and most people require a slow ramping on injectable glp-1s on a monthly basis if not longer of a time frame. I'll try to respect the patients' wishes on what they want to try and make my recommendations as well. If they're not seeing weight loss on current therapy I'll consider switching.
  • 3w
    I discuss with the patient the possible side effects that may limit the with ability to tolerate the medicine. If they have a poor diet and don’t exercise, it will be more difficult and less effective. I will switch when there are insurance coverage issues or if patient is not responding/losing weight or weight loss plateaus on the medication they are on.

Show More Comments